WallStSmart

Viavi Solutions Inc (VIAV)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viavi Solutions Inc generates 380% more annual revenue ($1.24B vs $258.90M). VIAV leads profitability with a -3.4% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

VIAV

Hold

39

out of 100

Grade: F

Growth: 4.7Profit: 3.5Value: 4.3Quality: 4.8
Piotroski: 3/9Altman Z: -47.67

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

VIAVSignificantly Overvalued (-44.2%)

Margin of Safety

-44.2%

Fair Value

$18.65

Current Price

$45.53

$26.88 premium

UndervaluedFair: $18.65Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

VIAV1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
36.4%10/10

Revenue surging 36.4% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

VIAV4 concerns · Avg: 2.8/10
Price/BookValuation
12.6x4/10

Trading at 12.6x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-5.5%2/10

ROE of -5.5% — below average capital efficiency

EPS GrowthGrowth
-73.4%2/10

Earnings declined 73.4%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : VIAV

The strongest argument for VIAV centers on Revenue Growth. Revenue growth of 36.4% demonstrates continued momentum. PEG of 1.34 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : VIAV

The primary concerns for VIAV are Price/Book, Piotroski F-Score, Return on Equity.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor COMMUNICATION EQUIPMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 39/100) and 43.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Viavi Solutions Inc

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Viavi Solutions Inc. provides network testing, monitoring and assurance solutions to communications service providers, enterprises, network equipment manufacturers, government, civil, military and avionics customers worldwide. The company is headquartered in San Jose, California.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?